CENTOGENE Announces Change in Supervisory Board

Cambridge, MA, USA & Rostock/Berlin, Germany, June 23, 2020 (Globe Newswire) – Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced that its Supervisory Board member Christoph Ehlers has resigned from office, effective June 15, 2020. After serving more than six years as member of the Company’s Supervisory Board, Mr. Ehlers has decided to step down due to personal circumstances.

“We are extremely grateful to Christoph for his contributions to CENTOGENE as both a member of the Supervisory Board and one of our initial stakeholders,” states Prof. Arndt Rolfs, CEO of CENTOGENE. “He has significantly contributed to the growth and direction of the Company. We are pleased that he will remain involved with CENTOGENE and continue to share his in-depth knowledge, extensive network, and experience. We wish him all the best in his future endeavours.”

“CENTOGENE has been a vital part of my life since 2008, and I am proud and grateful to have had the chance to participate in this marvellous corporate development for such a long time. I wish the Company and the team all the best for the future and will, of course, assist wherever possible,” stated Christoph Ehlers.

Media Contact

Ben Legg
Corporate Communications

FTI Consulting
Bridie Lawlor